1. Home
  2. GPUS vs KZIA Comparison

GPUS vs KZIA Comparison

Compare GPUS & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GPUS
  • KZIA
  • Stock Information
  • Founded
  • GPUS 1969
  • KZIA 1994
  • Country
  • GPUS United States
  • KZIA Australia
  • Employees
  • GPUS N/A
  • KZIA N/A
  • Industry
  • GPUS
  • KZIA Biotechnology: Pharmaceutical Preparations
  • Sector
  • GPUS
  • KZIA Health Care
  • Exchange
  • GPUS NYSE
  • KZIA Nasdaq
  • Market Cap
  • GPUS 4.1M
  • KZIA 6.0M
  • IPO Year
  • GPUS 1996
  • KZIA 1999
  • Fundamental
  • Price
  • GPUS $2.33
  • KZIA $0.96
  • Analyst Decision
  • GPUS
  • KZIA Strong Buy
  • Analyst Count
  • GPUS 0
  • KZIA 2
  • Target Price
  • GPUS N/A
  • KZIA $11.50
  • AVG Volume (30 Days)
  • GPUS 105.6K
  • KZIA 390.8K
  • Earning Date
  • GPUS 04-15-2025
  • KZIA 03-26-2025
  • Dividend Yield
  • GPUS N/A
  • KZIA N/A
  • EPS Growth
  • GPUS N/A
  • KZIA N/A
  • EPS
  • GPUS N/A
  • KZIA N/A
  • Revenue
  • GPUS $139,425,000.00
  • KZIA $1,655,324.00
  • Revenue This Year
  • GPUS N/A
  • KZIA N/A
  • Revenue Next Year
  • GPUS N/A
  • KZIA N/A
  • P/E Ratio
  • GPUS N/A
  • KZIA N/A
  • Revenue Growth
  • GPUS 3.50
  • KZIA 248000.00
  • 52 Week Low
  • GPUS $2.40
  • KZIA $0.76
  • 52 Week High
  • GPUS $20.30
  • KZIA $15.80
  • Technical
  • Relative Strength Index (RSI)
  • GPUS N/A
  • KZIA 42.17
  • Support Level
  • GPUS N/A
  • KZIA $0.78
  • Resistance Level
  • GPUS N/A
  • KZIA $1.44
  • Average True Range (ATR)
  • GPUS 0.00
  • KZIA 0.12
  • MACD
  • GPUS 0.00
  • KZIA 0.06
  • Stochastic Oscillator
  • GPUS 0.00
  • KZIA 21.54

About GPUS HYPERSCALE DATA INC

Hyperscale Data Inc, formerly Ault Alliance Inc is a diversified holding company. It operates a data center at which it mines Bitcoin and provides mission-critical products that support a diverse range of industries, including oil exploration, crane services, defense/aerospace, industrial, automotive, medical/biopharma, consumer electronics, hotel operations and textiles. The company has eight reportable segments: Energy and Infrastructure; Technology and Finance; SMC; Sentinum, Inc.; GIGA; TurnOnGreen; ROI; and Ault Disruptive.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.

Share on Social Networks: